Ruxotemitide

N/A

Report date: 2023/04/13 15:38:30

Base Information

Drug NameRuxotemitide
Drug Alias NameRuxotemitide - Lytix BiopharmaOncoporeLTX-315VP-315
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionImmunostimulantsApoptosis regulator Bcl-2 inhibitors
TargetsApoptosis regulator Bcl-2
Therapy Area/IndicationsSkin NeoplasmsHead and Neck NeoplasmsTriple Negative Breast Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSweden +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLytix Biopharma As
China Registration ClassN/A

Develop Information

Active CompaniesLytix Biopharma AsVerrica Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Basal CellMelanomaSarcoma
Inactive IndicationsSkin NeoplasmsHead and Neck NeoplasmsTriple Negative Breast Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A